Transcutaneous Auricular Vagal Nerve Stimulation Against Fatigue Syndrome in Patients with Long COVID: Results of the Randomized, Placebo-Controlled Clinical Pilot Trial COVIVA | Synapse
April 4, 2026Open Access
Transcutaneous Auricular Vagal Nerve Stimulation Against Fatigue Syndrome in Patients with Long COVID: Results of the Randomized, Placebo-Controlled Clinical Pilot Trial COVIVA
Puntos clave
To evaluate the efficacy of transcutaneous auricular vagal nerve stimulation on fatigue syndrome in long COVID patients.
Conducted a randomized, placebo-controlled clinical trial
Participants diagnosed with long COVID experiencing fatigue were enrolled
Transcutaneous auricular vagal nerve stimulation was administered to one group while the other received a placebo
The intervention group showed improvement in fatigue symptoms
Statistical analysis indicated significant differences between the treatment and placebo groups
Resumen
The trial was approved by the ethics committee (23/7798) and registered at the German Clinical Trials Register, identifier DRKS00031974.
Me gusta
Guardar
Compartir
Ver artículo completo
Cite This Study
Gierthmuehlen et al. (Thu,) studied this question.